Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ-; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

New data from efficacy study of CIMZIA in Crohn's disease patients presented

New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years.

27 Oct 2009

Dartmouth explores glucorticoid side effects on bladder-cancer patients

In her most recent study of possible triggers of cancer among northern New England residents, Dartmouth epidemiologist Margaret R. Karagas, Ph.D., and her team identified an enhanced risk to the bladders of patients taking drugs that suppress the immune system.

27 Oct 2009

UAB to create national database and repository to identify medications for rheumatoid arthritis

The University of Alabama at Birmingham (UAB) is spearheading an effort to create a national database and repository to enable researchers to identify predictors of effectiveness of various treatments for rheumatoid arthritis (RA).

24 Oct 2009

Cohen Independent Research Group publishes a report profiling Nutra Pharma

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that Cohen Independent Research Group has published a report profiling Nutra Pharma Corporation.

24 Oct 2009

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face competition from newer entrants.

23 Oct 2009

Aethlon Medical establishes ESI as a wholly owned subsidiary

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company.

23 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

Pharmos announces results of its Phase 2b Dextofisopam trial

Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome.

22 Oct 2009

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

CombinatoRx, Incorporated today announced the results of a 12 month knee osteoarthritis (OA) Phase 2 extension trial for Synavive™ (CRx-102) at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia. The data demonstrated that Synavive-treated subjects maintained efficacy levels throughout the 12 month extension trial.

21 Oct 2009

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb Company announced today that new clinical data support continued development of a subcutaneous administration of ORENCIA® (abatacept) for patients with moderate to severe rheumatoid arthritis.

21 Oct 2009

Biogen Idec announces total revenues of $1.12 billion for third quarter 2009

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today reported its third quarter 2009 results.

20 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Elan Corporation, plc and Biogen Idec today announced multiple presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in San Diego.

20 Oct 2009

RA patients who adhere to their prescription drug regimen have better outcome: Study

Rheumatoid arthritis (RA) patients who regularly adhere to their prescription drug regimen have fewer emergency room and doctor visits and incur lower medical costs, according to research presented today by Medco Health Solutions, Inc. at the American College of Rheumatology's Annual Meeting in Philadelphia.

20 Oct 2009

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

AstraZeneca and POZEN Inc. today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA.

20 Oct 2009

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

LX211 may become the first approved oral treatment for modifying the course of uveitis

New data from efficacy study of CIMZIA in Crohn's disease patients presented

Dartmouth explores glucorticoid side effects on bladder-cancer patients

UAB to create national database and repository to identify medications for rheumatoid arthritis

Cohen Independent Research Group publishes a report profiling Nutra Pharma

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Aethlon Medical establishes ESI as a wholly owned subsidiary

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Schering-Plough announces 2009 third quarter financial results

Pharmos announces results of its Phase 2b Dextofisopam trial

CombinatoRx announces Synavive Phase 2 extension trial results at the 2009 ACR meeting

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Biogen Idec announces total revenues of $1.12 billion for third quarter 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

RA patients who adhere to their prescription drug regimen have better outcome: Study

AstraZeneca and POZEN announce the pivotal data from two POZEN clinical trials

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in